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Abstract Diabetic kidney disease (DKD) is a devastating
complication that affects an estimated third of patients with
type 1 diabetes mellitus (DM). There is no cure once the
disease is diagnosed, but early treatment at a sub-clinical
stage can prevent or at least halt the progression. DKD is
clinically diagnosed as abnormally high urinary albumin
excretion rate (AER). We hypothesize that subtle changes
in the urine metabolome precede the clinically significant
rise in AER. To test this, 52 type 1 diabetic patients were
recruited by the FinnDiane study that had normal AER
(normoalbuminuric). After an average of 5.5 years of fol-
low-up half of the subjects (26) progressed from normal
AER to microalbuminuria or DKD (macroalbuminuria),
the other half remained normoalbuminuric. The objective
of this study is to discover urinary biomarkers that differ-
entiate the progressive form of albuminuria from non-
progressive form of albuminuria in humans. Metabolite
profiles of baseline 24 h urine samples were obtained by
gas chromatography–mass spectrometry (GC–MS) and
liquid chromatography–mass spectrometry (LC–MS) to
detect potential early indicators of pathological changes.
Multivariate logistic regression modeling of the meta-
bolomics data resulted in a profile of metabolites that
separated those patients that progressed from normoalbu-
minuric AER to microalbuminuric AER from those
patients that maintained normoalbuminuric AER with an
accuracy of 75% and a precision of 73%. As this data and
samples are from an actual patient population and as such,
gathered within a less controlled environment it is striking
to see that within this profile a number of metabolites
(identified as early indicators) have been associated with
DKD already in literature, but also that new candidate
biomarkers were found. The discriminating metabolites
included acyl-carnitines, acyl-glycines and metabolites
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related to tryptophan metabolism. We found candidate
biomarkers that were univariately significant different. This
study demonstrates the potential of multivariate data
analysis and metabolomics in the field of diabetic com-
plications, and suggests several metabolic pathways rele-
vant for further biological studies.
Keywords Diabetic kidney disease  Nephropathy 
Metabolite profile  Metabolomics  Urine  GC–MS 
LC–MS  Multivariate data analysis
1 Introduction
As the number of patients with diabetes increases, diabetic
kidney disease (DKD) is a growing public health problem.
An estimated third of type 1 diabetic patients will develop
DKD over the course of several decades after diabetes
onset (Finne et al. 2005; Gross et al. 2005). These diabetes
patients have a 10-fold risk of premature death due to
cardiovascular and other circulatory diseases, and the risk
increases even more for those who develop renal failure
(Ma¨kinen et al. 2008; Groop et al. 2009; Soedamah-Muthu
et al. 2004). Typical clinical manifestations of DKD
include increased urinary albumin excretion rate (AER)
and rising blood pressure, histological manifestations
include the Kimmelstiel–Wilson nodules in the glomerulus
(Kimmelstiell and Wilson 1936). DKD cannot be cured at
present, but improved glycemic control and aggressive
treatment of high blood pressure can halt the progression of
the disease, especially when administered at an early stage
of DKD (Lachin et al. 2000; Thomas and Atkins 2006).
AER is the primary diagnostic biomarker for DKD in
clinical practice. Elevated levels of AER measured at fol-
low-up times with respect to the AER levels measured at
baseline indicate if a patient is suffering a progressive form
of DKD. For healthy individuals it is not uncommon to find
elevated levels of AER which are clinically at the edge of
microalbuminuria, but have no damage of the kidney
function, therefore AER is not an early predictive marker
or a quantitative measure of the kidney function at an early
stage of kidney disease (Caramori et al. 2006). It may be
possible that subtle alterations in metabolic pathways pre-
cede the changes that manifest as macroalbuminuria. These
changing levels of the related low-molecular weight
metabolite profiles may therefore be useful as early
markers of a progressive form of DKD.
Mass spectrometry-based metabolomics has been
extensively applied in disease diagnostics (Johnson 2005;
Jankevics et al. 2009). Nevertheless, there are only a
handful of similar studies of human DKD (Ma¨kinen et al.
2006; Ma¨kinen et al. 2008; Zhang et al. 2009) most of
which were based on serum samples and differentiated
between patients suffering from DKD and a healthy control
group. In this study, urine samples from 52 type 1 diabetic
patients from the FinnDiane Study that were clinically
defined as having a normal AER (\30 mg/24 h, Ma¨kinen
et al. 2006) were profiled. Half of this group (26 patients)
suffered from the progressive form of albuminuria; the
other half did not show a progression in albumin excretion.
Both gas chromatography–mass spectrometry (GC–MS)
and liquid chromatography–mass spectrometry (LC–MS)
were used to analyze a wide range of metabolites in these
urine samples. The data was from an actual patient popu-
lation measured within a less controlled environment. As
changes in biological samples are often multifactorial
(Zhang and Chan 2005; Qiu et al. 2008), both univariate
and multivariate data analyses were used. The multivariate
metabolite profiles to differentiate between the two groups
were found using logistic regression (LR) with variable
selection. Based on MSn fragmentation experiments
(LC–MS only), manual interpretation combined with
database searches we could identify several of the dis-
criminating compounds that may be relevant for further
biological studies.
2 Experimental
2.1 Samples
At baseline, type 1 diabetic patients were recruited by the
Finnish Diabetic Nephropathy Study Group (FinnDiane).
The initial data collection was cross-sectional (serum and
urine samples), but with longitudinal records of albumin-
uria and clinical history. These study patients suffering
from type 1 diabetes mellitus had an age of onset below
35 years and a transition to insulin treatment that occurred
within a year after onset. The classification of renal status
was made centrally according to urinary albumin excre-
tion rate (AER) in at least two out of three consecutive
overnight or 24 h-urine samples. Absence of diabetic
kidney disease was defined as AER within the normal
range (AER \20 lg/min or \30 mg/24 h). Prospective
clinical data were available for a subset of patients, all
being male. There were 26 subjects that progressed from
normal AER to microalbuminuria (PR) and had urine
samples available at the time having normal AER. 26
clinically group-matched (age, diabetes duration, baseline
albuminuria status, sex) non-progressive AER (NP) sub-
jects were selected as study reference. Subjects for this
group (NP) that had a long follow-up were preferentially
included. Table 1 shows some clinical characteristics of
these subjects for the non-progressive AER and progres-
sive AER groups. A more detailed table is included in the
supplement (Table S1).
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2.1.1 GC–MS
All urine samples were processed and analyzed once using
a randomized sample sequence over multiple batches. After
every 6th study sample a quality control (QC) sample was
injected. The QC sample was obtained by taking an aliquot
of the same volume of all urine samples from this study.
They were prepared once and measured in duplicate. All
urine samples were analyzed with GC–MS according to the
method described below.
2.1.2 LC–MS
The urine samples of the normal AER subjects were split
into two aliquots, which were independently processed by
the sample-pretreatment. Each extract was subsequently
analyzed by LC–MS once so that for each sample from the
normal AER group in total two LC–MS analyses were
obtained. A pooled QC sample (the same as for GC–MS)
was analyzed after every 6th sample.
2.2 Materials
2.2.1 GC–MS
For the GC–MS analysis, pyridine and N-methyl-N-tri-
methylsilyl trifluoroacetamide were obtained from Mal-
linckrodt Baker BV (Deventer, The Netherlands) and
Alltech (Breda, The Netherlands), respectively. Standards
were purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands).
2.2.2 LC–MS
For the LC–MS method, LC–MS grade acetonitrile (AcN)
and MS-grade water were obtained from Biosolve
(Valkenswaard, The Netherlands). All standards were
purchased from Sigma-Aldrich, except for phenylalanine-
d5, which was from C/D/N Isotopes Inc. (PointeClaire,
Quebec, Canada). Acetic acid, formic acid and sodium
hydroxide were obtained from Biosolve (Valkenswaard,
The Netherlands), Acros Organics (Geel, Belgium) and
Merck (Darmstadt, Germany), respectively.
2.3 Sample preparation
2.3.1 Initial sample preparation
Urine samples (stored at -80C) from FinnDiane were
thawed at room temperature, homogenized using a vortex
and centrifuged at 7500 g for 20 min. Specific volumes
from the supernatant (typically 100 or 50 ll) were taken
and 10 vol% aliquots of a 1 M acetic acid solution
(adjusted to pH 6.0 with solid sodium hydroxide) were
added and stored in vials. Samples were then stored at
-80C prior to method specific sample preparation.
2.3.2 GC–MS specific sample preparation
Sample preparation for GC–MS analysis was done similar
to the method described elsewhere (Koek et al. 2006). In
short, samples and standard urine solutions were thawed at
room temperature and homogenized using a vortex. All
80 ll samples were mixed with 10 ll solutions containing
the internal quality standards leucine-d3, glutamic acid-d3,
phenylalanine-d5 and cholic acid-d4 (each present at a
concentration of about 250 lg/ml in methanol/water (1:4
v/v)) and subsequently lyophilized at -37C in autosam-
pler vials. The internal quality standards alanine-d4 and
glucose-d7 in pyridine (each about 250 lg/ml) were added
to the dry extracts prior to oximation. Oximation (90 min
at 40C) was performed after adding 20 ll of a 56 mg/ml
ethoxyamine hydrochloride solution in pyridine and 20 ll
of pyridine to the extracts. Next, a 10 ll mixture of tri-
fluoracetylanthraceen, dicyclohexylphthalate (DCHP) and
difluorobiphenyl (each at a concentration of 250 lg/ml in
pyridine) was mixed with the extracts and the mixtures
were silylated for 50 min at 40C with 200 ll of N-methyl-
N-trimethylsilyl trifluoroacetamide. Then the samples were
centrifuged (500 g for 20 min) and the supernatant was
taken for analysis by GC–MS. The final GC–MS prepared
samples were containing standards at a concentration of
10 ng/ml each. More details are given in the supplement.
2.3.3 LC–MS specific sample preparation
The FinnDiane urine samples were thawed at room tem-
perature and subsequently mixed using a vortex. Next, the
urine was centrifuged (7500 g for 10 min) at room tem-
perature. To obtain the LC–MS samples, 35 ll of the
Table 1 Clinical characteristics of the subjects at baseline
Clinical parameters
(Normoalbuminuric)
Non-progressive Progressive
Number of samples (Male) 26 26
Age (years) 36 ± 9 35 ± 10
Blood pressure (mm Hg) 80/132 ± 8/10 82/132 ± 11/15
BMI (kg/m2) 25 ± 2 27 ± 3
Serum creatinine (lmol/l) 88 ± 14 86 ± 13
AER (mg/24 h) 12 ± 6 14 ± 7
HbA1c (%) 8 ± 1 9 ± 1
Diabetes duration (years) 27 ± 6 18 ± 11
Follow-up time (years) 6 ± 1 5 ± 2
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supernatant was transferred into an autosampler vial and
mixed with 10 ll of the internal standards mix (valine-d8,
phenylalanine-d5, tryptophan-d5, thymine-d4 and reserpine
in water at a concentration of 21, 21, 21, 35 and 7 lg/ml,
respectively) and 25 ll water.
For the validation of the LC–MS method (see supple-
ment), two urine samples of one normoalbuminuric dia-
betic and one healthy volunteer were mixed in a 1:1 ratio.
To 500 ll urine, 100 ll of a solution of 1 M acetic acid
(adjusted to pH 6.0 with sodium hydroxide), 50 ll of the
internal standards mix (valine-d8, phenylalanine-d5, tryp-
tophan-d5, thymine-d4 and reserpine in water at a con-
centration of 60, 60, 60, 100, 20 lg/ml, respectively) and a
varying volume of the calibration mix (phenylalanine,
tryptophan and salicylamide in water at a concentration of
100 lg/ml) were added. Subsequently, water was added so
that finally 1000 ll of validation sample was obtained for
each calibration concentration. The samples were centri-
fuged (7500 g for 10 min) and the supernatant was ana-
lyzed by the LC–MS method. More details are given in the
supplement.
2.4 Identification of metabolites
High resolution mass spectra were acquired using the 1200
Agilent gradient LC system coupled to a linear ion trap–
Fourier transform (LTQ-FT) hybrid mass spectrometer and
a LTQ-orbitrap mass spectrometer (both from Thermo
Fisher Waltham, MA) Both systems were equipped with an
ionmax ESI source. Spectra were recorded only in positive
ESI centroid ion mode, with a source temperature of
275C, source voltage of 4 kV and a sheath gas of 40 AU.
2.4.1 FT
LTQ-FT was setup for a MS3 scanning method. Resolution
was set to 12500 for all events to decrease scan time. Scan
event one was a full scan with a scan range from 120 to
1000 m/z. Scan event two was set to fragment one of the
targeted masses with a CID energy of 35% and isolation
width of 1.5 m/z. Scan event three was set to Data
Dependent scan where it was set to fragment the most
intense ion from scan event two with CID of 35% and
isolation width of 1.5 m/z. All spectra were recorded in FT-
mode with a typical mass accuracy of \1.5 ppm for both
full scan and MS/MS spectra.
2.4.2 Orbitrap
The LTQ-orbitrap was setup for (MS3) HCD fragmentation
measurements. Resolution was set to 7500 for all events to
decrease scan time. Scan event one was setup for a full
scan with a scan range from 120 to 600 m/z. Scan event
two was set to fragment one of the targeted masses in HCD
fragmentation mode with a HCD energy of 30% and iso-
lation width of 1.5 m/z. Scan event three was set to frag-
ment one of the targeted masses in HCD fragmentation
mode with a HCD energy of 50% and isolation width of
1.5 m/z. All spectra were recorded in FT-mode with lock
masses 279.15909 and 391.28429 m/z in full scan. Mass
accuracy in full scan spectra was\2 ppm and in HCD MS–
MS spectra \4 ppm.
2.4.3 Interpretation of the spectra
The spectra were collected and molecular formulae were
then calculated by an in-house developed software tool
using MS3 fragmentation data. Spectra together with
molecular formulae were further interpreted manually. The
compounds that were identified were confirmed by com-
parison to spectra found in databases such as HMDB and
by authentic standards where possible.
2.5 Data processing and analysis
2.5.1 GC–MS
After sample analysis with GC–MS a target table of all
relevant peaks (with known and unknown identity) was
constructed. For this, a standard target table containing over
300 entries of endogenous plasma metabolites and urine
specific peaks was used ultimately leading to a target list of
144 compounds. These compounds were integrated using a
reconstructed ion chromatogram of a characteristic ion of
each compound. The internal standards were quantified in
the same manner. The GC–MS data have been corrected for
internal standard response using DCHP followed by QC
correction as described earlier (van der Kloet et al. 2009).
2.5.2 LC–MS
After analysis of all samples using LC–MS a small subset
of samples that contained 2–3 samples of each albuminuric
class was used for screening compounds using software
provided by Bruker-Daltonics (DataAnalysis). The m/z
resolution was set to 0.01 Da, the minimum S/N ratio was
set to 3 and to prevent integration problems the retention
time window was set to 20 s. This resulted in a target list of
about 600 features, where each feature was characterized
by a retention time and a mass, and which could represent a
metabolite. One metabolite can have multiple features.
This target list was used as input for the software package
Quant-Analysis by Bruker-Daltonics to create extracted ion
chromatograms (EICs) for all peaks for all LC–MS sam-
ples. In this way a peak table was constructed that was
further narrowed down by removing features that had lots
112 F. M. Kloet et al.
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of missing values or no response at all in the QC samples
(Bijlsma et al. 2006). As the dead time of the LC–MS
method was 1 min, features detected with retention times
lower than 2 min were discarded. Features with large dif-
ferences in retention time (RSD higher than 5%) were
removed as well. This resulted in a final peak table of 106
features. For the LC–MS data the response has been cor-
rected using the most optimal internal standard as descri-
bed earlier (van der Kloet et al. 2009).
2.5.3 GC–MS and LC–MS sample normalization
For further statistical analysis the feature representing
glucose (indicative for diabetes) was removed from the
data. For healthy subjects the response of urine samples is
often normalized by its creatinine level. In the case of
varying degrees of kidney failure (i.e. microalbuminuric or
macroalbuminuric), the creatinine levels cannot be used for
normalization because they show irregular behavior due to
diabetes and/or medication. Furthermore, a recent report
shows that the creatinine concentration may vary over a
large scale and that variances in urinary metabolite con-
centrations are not due to urine dilution effects; rather, they
reflect actual metabolite variances (Jankevics et al. 2009;
Saude et al. 2007). To circumvent this, as a means of
normalization per sample, row scaling (i.e. subject nor-
malization) was applied by taking the sum of the peak areas
of all the components measured and dividing the response
of each metabolite in a sample by this sum (Kemperman
et al. 2007). For LC–MS measurements duplicates were
averaged per metabolite after visual inspection. All data
were auto-scaled prior to further multivariate statistical
analysis.
All multivariate data analyses were performed using
Matlab 2008a (Mathworks 2008). The PCA charts were
created using the PLS-toolbox 5.5.2 from Eigenvector
Research (2008).
3 Results and discussion
3.1 Data processing and quality
The LC–MS method was set up and successfully validated
for urine (for details, see supplement), while the GC–MS
method validation results were published earlier (Koek
et al. 2006). To monitor the stability of the analytical
system, quality control (QC) samples were measured dur-
ing both GC–MS and LC–MS analyses. In these QC
samples the responses of each compound should be con-
stant over time. The stability of the response per compound
is expressed in relative standard deviation (RSD) values, in
which case for each metabolite the standard deviation of
the response in all QC samples is divided by the average of
the response in all QC samples. Large RSD values of
response indicate poor repeatability, which can be assigned
to instability of the analytical system or due to other
variations such as instability of the analyte, etc. For GC–
MS a total of 144 compounds were measured of which 106
had an RSD of less than 10% in the QC samples. The
remainder was predominantly in the RSD range of 10–20%
(for 9 compounds the RSD value was larger than 30%). For
LC–MS, 106 features were found of which 65 had an RSD
value of 10–20% and of which the remainder was pre-
dominantly in the 20–30% RSD range (for 8 compounds
the RSD value was larger). 130 compounds (GC–MS) and
89 features (LC–MS) were selected for further data anal-
yses based on RSD values less than or equal to 25%.
3.2 GC–MS results
Univariate tests for significant difference between non-
progressive and progressive AER subjects [t-tests and
Wilcoxon tests (Miller and Miller 2005)] were executed for
each compound at a 95% significance level. The proba-
bility of a Type I error (i.e. the error of rejecting a null
hypothesis when it is actually true) was further reduced
using the Bonferroni approach by setting the significance
level to a = 0.05/130 & 0.00039. None of the tested
compounds showed a significant difference.
Principal component analysis (PCA), an unsupervised
multivariate data analysis method, was used to investigate
whether there was an apparent metabolomic separation
between the non-progressive normo AER subjects vs. the
progressive AER subjects. Using the GC–MS data of all
metabolites, PC1 vs. PC2 did not show any clear separation
Fig. 1 PCA score plot of the GC–MS data of urine from normal AER
subjects using 130 compounds
Early-stage biomarkers for diabetic kidney disease 113
123
between the two groups, whereas PC1 vs. PC3 (Fig. 1)
showed some clustering of the two classes.
Because no clear separation was visible in the PCA
score plot, supervised multivariate data analysis was used.
As the classification problem had a dichotomous outcome
(progressive or non-progressive), we used multivariate
logistic regression (LR) in which the data was modeled in
such a manner that the predicted outcome was always
bounded between zero and one (corresponding with the 2
groups) (Westerhuis et al. 2008; Hastie et al. 2008). The
choice of logistic regression was made because an ordinary
linear regression method assumes that in the population a
normal distribution of error values around the dependent
variable is associated with each independent variable, and
that the dispersion of the error values for each of these
independent values is the same. However, the distribution
of errors for any independent value cannot be normal when
the distribution has only two values (Pampel 2000). To
prevent over-fitting we used cross-validation followed by
permutation tests. The choice of logistic regression in
combination with variable selection allowed us to deal with
the heterogeneity of the data and obtain stable cross vali-
dated models (for details see supplement).
The comparison between normal AER PR and normal
AER NP subjects rendered a cross-validated logistic regres-
sion model with an accuracy of 65% and a precision of 64%.
Ultimately 65 out of the 130 available metabolites were left in
the final model. Accuracy can be viewed as the ‘‘overall
effectiveness of a classifier’’ and precision as ‘‘class agree-
ment of the prediction with a specific class (e.g. progressive,
non-progressive)’’ (Sokolova and Lapalme 2009). Details
regarding the cross-validation, the exact definition of accu-
racy and precision can be found in the supplement (Table S3).
To obtain a list of candidate biomarkers that form the
predictive metabolic profile using this multivariate model,
the significant contribution of each of these biomarkers to the
model and the model itself was evaluated as described below.
Permutation tests by means of randomizing the class mem-
bership vector were performed to evaluate the significance of
the logistic regression model differentiating the non-pro-
gressive from the progressive normoalbuminuric subjects
(see Supplement). The unpermuted model showed a ten-
dency towards being significant (16 out of 100 permuted
models gave equal or better classification results).
Furthermore, using the regression vectors obtained from
the permutation tests the significance of the contribution to
the logistic regression model for each of the 65 compounds
was determined. In total 34 compounds were found to be
significant with a P-value lower than 0.05 (at most 5 out of
100 permuted models had a larger regression coefficient
than the unpermuted model, see Supplement). Table 2 lists
those compounds (21 in total) that were identified from this
list of 34 compounds, ranked by their significance, together
with their up-regulation (i.e. the relative concentration
increased for the PR samples compared to the NP samples),
their multivariate P-value and t-test P-value.
3.3 LC–MS results
With a Bonferroni corrected a of 0.00056 (0.05/89), 3 out
of the 89 features showed significantly different group
means with either a t-test or a Wilcoxon test (Fig. 2). As
most of the statistically relevant features so far had not
been identified in our lab for the LC–MS method, they
were subjected to identification using high resolution MS
and multi-stage MS/MS (see Experimental). Table 3 lists
these three compounds, their respective P-values and their
up-regulation (i.e. the relative concentration increased for
the PR samples compared to the NP samples).
The PCA score plot of LC–MS results of the normal
AER subjects (Fig. 3) showed some clustering along the
diagonal of the first and second principle component of the
progressive and non-progressive subjects.
Analogue to the GC–MS data analysis, LR with variable
selection was used. The resulting model contained 42
features. The accuracy of the cross-validated logistic
regression model for the binary classification of NP vs. PR
was 75% with a precision of 73%.
To evaluate the significance of metabolites contributing to
the LC–MS based LR model differentiating between non-
progressive and progressive normoalbuminuric subjects, and
the model itself, permutations test were performed. The
model was found to be significant; only 4 out of 100 per-
muted models gave equal or better classification results (see
Supplement). Using the regression vectors from the permu-
tation tests, the significance of each of the 42 features was
determined. 14 features were significant (at most 5 out of 100
permuted models had a larger regression coefficient than the
unpermuted mode, see supplement). High resolution MS and
multi-stage MS/MS (see Experimental) were used to identify
these features. Table 4 lists 8 of these 14 features that were
identified ranked by significance, together with their up-
regulation (i.e. the relative concentration increased for the
PR samples compared to the NP samples) and the univariate
t-test P-value. Literature study revealed that several com-
pounds that were identified with a multivariate significance
higher than a P-value of 0.05 could be linked to DKD. As
these compounds also contributed to the model, these com-
pounds were added to Table 4. Note that the compounds that
showed a univariate significance were also included in the
LR model (Table 4).
3.4 Strengths and weaknesses
Both GC–MS and LC–MS data suffer from heterogeneity
in the (samples of the) study population. The origin of this
114 F. M. Kloet et al.
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heterogeneity is the result of multiple factors, the main
ones are: (i) the difficulty to obtain an exact kidney phe-
notype, as discussed in the introduction; AER is the pri-
mary diagnostic biomarker in clinical practice, but its
usefulness as an early marker is limited due to high natural
variance (Caramori et al. 2006); and (ii) the uncontrolled
environment in which the urine samples were taken (e.g.
urine metabolite concentrations depend on diet, variation
due to slight differences in sampling 24 h urine, etc.). This
heterogeneity and the small number of prospective samples
severely complicated proper statistical analyses. In cross-
validating the binary classification models, the leave two
out strategy was used (1 sample was left out for each class).
In order to select those features/compounds in the model
that were specific for the whole dataset and not just for a
few samples, a variable selection method (see above) was
included. It turned out that when a subset of variables was
used more accurate predictive models were obtained that
were less susceptible to different training/test-set schemes
(data not shown). Although the number of prospective
samples is small the nature of the data (i.e. urine samples at
an early stage of diabetic kidney disease) and the fact that
some of the found biomarkers were already related to DKD
the obtained results certainly give rise to future research.
3.5 Biological context of the new candidate biomarkers
Reviewing the metabolites in Table 2 it is interesting to
note that many of the GC–MS compounds are carboxylic
compounds and/or acidic metabolites that are prevalently
detected in urine (Lawson et al. 1976) (5-hydroxymethyl-2-
furancarboxylic acid, benzoic acid and hippuric acid).
Others are endogeneous amino acids (valine, serine). From
the identified compounds, we have not found any docu-
mented direct relation to DKD. Deoxyfructose could be
related to a phenomenon called ‘‘diabetic stress’’ in which
deoxyglucosone is converted to the less reactive deoxy-
fructose (Knecht et al. 1992). Galactonic acid has been
associated with diabetic retinopathy (Kador et al. 2002).
Rainey et al. already suggested an interaction of 5-hydro-
xymethyl-2-furancarboxylic acid with galactonic acid
(Mrocheck and Rainey 1972).
Table 2 Metabolites discriminating progressive and non-progressive normal AER subjects using the logistic regression of GC–MS data
Compound Up-regulationa Significanceb t-test P-value
4-Oxoprolinec -1 0 0.03
Pseudouridined 1 0 0.41
3,4,5-Trihydroxypentanoic acide -1 0 0.09
Deoxyfructosec 1 0 0.80
3-Hydroxy-3-(3-hydroxyphenyl) propanoic acide 1 0 0.58
L-Valined 1 0.01 0.25
2,3-Dihydroxy-3-methylbutanoatec -1 0.01 0.27
5-Hydroxymethyl-2-furancarboxylic acide -1 0.02 0.09
Galactonic acide -1 0.02 0.01
2-Hydroxyvaleric acidc 1 0.02 0.58
N-formylproline or N-ethylprolinec -1 0.02 0.00
2-Hydroxyglutaric acidd 1 0.02 0.51
N-(3-hydroxybenzoyl)glycinee 1 0.02 0.47
L (?) Arabinosed -1 0.03 0.13
Benzoic acidd -1 0.03 0.04
3-Hydroxyphenylacetic acidd -1 0.03 0.01
Glucuronide compoundc 1 0.03 0.32
D-Glutamicacidd -1 0.05 0.04
Gluconicacidd 1 0.05 0.04
Glycolicacidd -1 0.05 0.05
L-Cystined 1 0.05 0.37
a Increased concentration for progressive subjects, i.e. positive for progression: 1, decreased concentration for progressive subjects: -1
b The number of times that the metabolite in a permuted model had a larger regression coefficient than the unpermuted model divided by the
total number of permutations executed
c Compounds were characterized, and only the class of metabolite could be suggested
d Compounds were identified, and the identity confirmed by an authentic standard
e Compounds were annotated based on elemental composition and by comparison to reference libraries
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The metabolites in LC–MS (Table 4) are either: (1)
acylcarnitines, (2) acyl-glycines, (i.e. salicyluric acid,
hippuric acid, (2-phenylacetoxy- propionyl) glycine and
3-methylcrotonylglycine) and (3) compounds related to the
tryptophan metabolism (i.e. tryptophan, indoleacetic acid
and kynurenic acid).
It is perhaps not that straightforward to link the
metabolites to a specific pathway as a recent study already
demonstrated that many of the acylglycines and tryptophan
metabolites in mammalian blood have shown a relation to
gut ‘‘microbiome’’ (Wikoff et al. 2009) which could
explain a presence in urine by regular excretion.
In general, acyl-carnitines are formed in the fatty acid
metabolism pathway to transport the long-chain acyl
groups of fatty acids into mitochondria, where these groups
are broken down through ß-oxidation to acetate to obtain
energy via the citric acid cycle. Under normal homeostasis
conditions, carnitine is eliminated by excretion in urine, in
both free and esterified forms, mainly as acetylcarnitine
(Chalmers et al. 1984). A higher acylcarnitine to carnitine
ratio in urine in relation to plasma is suggested to be the
result of a less efficient reabsorption of acylcarnitines or of
a renal acylation of carnitine followed by leakage of the
locally formed acylcarnitine product into urine (Vernez
2005; Wagner et al. 1986; Rebouche and Seim 1998) .
Glycine conjugation is an effective detoxification sys-
tem for preventing accumulation of acyl-CoA esters in
several inherited metabolic disorders. Acylglycines in urine
0.1
0.15
0.2
Hippuric acid
p = 0.00031
0
0.5
1
1.5
2
2.5
3
x 10-3
Progressive Non-progressive Progressive Non-progressive
S-(3-oxododecanoyl)cysteamine
p = 0.00045
2
4
6
8
x 10-3
Progressive Non-progressive
Substituted carnitine
p = 0.00006
Fig. 2 Boxplots of the 3
compounds that showed
significant group means
Table 3 The 3 metabolites that show a statically relevant difference between the group means of the progressive group and non-progressive
normoalbuminuric group
Compound P-value Up-regulationa
t-test Wilcoxon
Substituted carnitineb 0.00000592 0.00000368 1
Hippuric acidc 0.00003066 0.00004267 -1
S-(3-oxododecanoyl) cysteaminec 0.00004540 0.00003714 1
a 1 means increased concentration for progressive subjects, i.e. positive for progression, -1 means decreased concentration for progressive
subjects
b Compounds were characterized, and only the class of metabolite can suggested
c Compounds were annotated based on elemental composition and MS/MS (e.g. by comparison to reference libraries)
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have been reported as the direct expression of accumula-
tion of the correspondent acyl-CoA esters in the mito-
chondrion (Bonafe et al. 2000).
Tryptophan metabolism changes with DKD have been
reported before (Bonafe et al. 2000), where tryptophan
plasma concentration in animals with experimental renal
failure decreased while a simultaneous increase of metab-
olites related to the kynurenine pathway (e.g. kynurenic
acid) in plasma were observed. It was demonstrated in
animals that the content of kynurenic acid in kidneys is the
highest among all tissues (Lou et al. 1994). Furthermore, it
has been known that kynurenic acid is the main metabolite
excreted from organism (rats) by means of tubular secre-
tion. In renal failure this mechanism is considerably
impaired, which in consequence leads to excessive accu-
mulation of this substance in the organism (Pawlak et al.
2002).
Of interest are the elevated levels of 2-(2-phenylacet-
oxy)propionylglycine in the progressive patients. In the
absence of medium chain acyl-CoA dehydroxygenase
(MCAD) phenylpropionacid is converted to phenylpropi-
onglycine instead of benzoic acid. Phenylpropionglycine is
detected only in the urine of MCAD-deficient patients and
has been used as a biomarker for the diagnosis of this
condition (Wikoff 2009). However, in summary, it should
be mentioned that further research is required to investigate
the biochemical context of all the candidate biomarkers in
more detail.
4 Conclusions
It was demonstrated that based on LC–MS measurements
of urine samples a statistically significant multivariate
model could be constructed to distinguish between
Fig. 3 PCA score plots of the LC–MS data of the urine samples from
Normal AER subjects using 89 features
Table 4 Identified compounds from the metabolites discriminating most between progressive and non-progressive normoalbuminuric subjects
using logistic regression model of LC–MS data
Compound Up-regulationa Significanceb t-test P-value
Tryptophanc 1 0 0.00
Salicyluric acidc 1 0.01 0.09
Substituted carnitined 1 0.01 0.00
S-(3-oxododecanoyl) cysteaminee 1 0.01 0.00
Hippuric acide -1 0.02 0.00
Substituted carnitined 1 0.02 0.00
N-methyl guanosinee 1 0.04 0.00
Substituted carnitined 1 0.05 0.00
Kynurenic acidc 1 0.08 0.18
2-(2-phenylacetoxy)propionylglycinee 1 0.09 0.45
Substituted carnitined -1 0.09 0.36
Indoleacetic acidc -1 0.1 0.15
3-methylcrotonylglycinee 1 0.1 0.03
Heptanoylcarnitined 1 0.1 0.00
a 1 means increased concentration for progressive subjects, i.e. positive for progression, -1 means decreased concentration for progressive
subjects
b The number of times that a metabolite in a permuted model had a larger regression coefficient than the unpermuted model divided by the total
number of permutations executed
c Compounds were identified, and the identity confirmed by an by an authentic standard based on MS/MS and retention time
d Compounds were characterized, and only the class of metabolite can suggested
e Compounds were annotated based on elemental composition and MS/MS (e.g. by comparison to reference libraries)
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progressive and non-progressive subjects within the normal
AER group with an accuracy of 75%. Many of the com-
pounds contributing to the model could be grouped in one
of three classes, i.e. acyl-carnitines, acyl-glycines and
compounds related to the tryptophan metabolism. All of the
compounds that were measured that show a univariate
significant difference between the two groups were inclu-
ded in the metabolic profile defined by the multivariate
model. The metabolic profile also included metabolites that
did not show a univariate significant difference and
emphasizes the additional benefit of multivariate statistics
over univariate statistics alone in preventing overlooking
candidate biomarkers.
Future research will focus on the discovery of additional
biomarkers using complementary metabolomics platforms
and the validation of the explorative biomarker profiles
with a validation set. In addition, more effort will be
directed to the biological interpretation: it will be investi-
gated which pathways were involved in the biochemical
changes associated with the onset, development and pro-
gression of DKD, and whether these changes are the same
during onset and progression, or if different changes of
biochemistry occur at the different stages of DKD, e.g. due
to the disease pathology or due to the use of medication
after onset of DKD. In summary, the results obtained
demonstrate the potential of metabolomics in the study of
diabetic complications, as subtle changes in the urine me-
tabolome precede the clinically significant rise in AER.
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